Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Circulating Tumor Cells and CLDN Expression in Zolbetuximab Therapy for HER2-Negative Gastric Cancer
jRCT1071250066Recruiting
- Sponsor
- Astellas Pharma
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Single-arm trial of zolbetuximab in gastric adenocarcinoma, sponsored by Astellas Pharma. Primary endpoint: Primary: Relationship of CLDN expression between primary tumors and circulating tumor cells. Started Sep 2025; status: recruiting.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on jRCT1071250066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071250066.